Funding for this research was provided by:
Alzheimer's Society (AS-PG-2013-017)
Received: 7 February 2019
Accepted: 13 September 2019
First Online: 21 October 2019
Ethics approval and consent to participate
: Written consent was obtained for participation in the CFAS study. Ethical approval was obtained locally at all sites from 1991 and at Multi-centre research ethics committees during the course of the study (further detail on all ethical approvals can be found at ExternalRef removed). For example, the first multi-centre ethical approval was obtained at the Anglia & Oxford multi-centre research ethics committee (ref: 99/5/22).
: Not applicable.
: The authors declare that they have no competing interests, other than IM has received personal fees for guest lectures and to support travel from Astellas Pharmaceuticals; YL reports personal fees from Thame Pharmaceuticals, NC and CF have received grants and personal fees from Astellas Pharmaceuticals.